On Demand Webinar

Translational Biomarker Lab - Unlocking the Future of Cancer Treatment

The intricate landscape of oncology drug development necessitates robust biomarker strategies to enhance translational efficacy and accelerate clinical progression. This webinar, presented by Crown Bioscience and led by Julie Ann Mayer, PhD, Vice President, Global Biomarker Platform, provides an in-depth exploration of integrated biomarker services, designed to optimize your oncology and immuno-oncology programs from discovery through clinical development.

Gain real-world expertise into:

• Translational & Clinical Biomarker Ecosystems: Delve into the comprehensive spectrum of laboratory services supporting biomarker discovery, validation, and clinical application.
  
  
• Multi-Omics and Spatial Technologies: Investigate the utility of cutting-edge platforms including multi-omics biomarker assays, spatial omics, advanced digital pathology, quantitative genomics/transcriptomics, soluble protein analysis, flow cytometry, and mass spectrometry-based proteomics.
  
  
• Data-Driven Decision Making: Understand the integration of expert bioinformatics and AI-enhanced analytics to derive actionable insights from complex datasets, yielding publication-ready outcomes.
  
  
• Applied Case Studies: Review empirical data from case studies illustrating the successful implementation of integrated solutions in discovery to translational oncology.
  
  
• Strategic Collaboration & Resources: Discover Crown Bioscience's capabilities in providing bespoke solutions, leveraging collaborative scientific expertise, and accessing extensive biobank resources to propel your research initiatives.

Watch Now

Meet Our Presenter:

Julie Ann Mayer, PhD, Vice President, Global Biomarker Platform, Crown Bioscience

Dr. Julie Mayer joined Crown Bioscience from NeoGenomics Laboratories, where she served as Vice President of Molecular Strategy, overseeing the R&D organization largely focused on developing comprehensive, high-throughput NGS and novel technology/applications.

Dr. Mayer has held progressive scientific and leadership roles spanning R&D and Operations at several molecular diagnostics companies, including NeoGenomics Laboratories, Biocept Inc., Navigate BioPharma Services (a Novartis subsidiary), Genoptix (a former Novartis subsidiary), Menarini Silicon Biosystems, and Quest. She has extensive precision medicine experience, having developed, validated, and launched >50 diagnostic assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories.

Before joining industry, Dr. Mayer received her post-doctoral training in translational breast cancer research at Baylor College of Medicine and in clinical cancer prevention at MD Anderson Cancer Center.

Dr. Mayer obtained her Ph.D in Pathology and Master’s of Science in Experimental and Molecular Pathology both from the University of Southern California, and a Bachelor’s degree in Biology from the University of California Riverside.